Abstract：Objective To further evaluate the value of the stereotactic gamma-ray body radiation therapy (γ-SBRT) for patients with stage Ⅰ/Ⅱ non-small cell lung cancer (NSCLC) basing on the preliminary studies. Methods Twenty-nine eligible patients with stage Ⅰ/Ⅱ NSCLC who is unable or unwilling to receive surgery underwent treatment prospectively with γ-SBRT (OUR-QGD). Patients were fixed by vacuum bag. Each patient underwent slow CT simulation at 5 s/slide with thickness of 5 mm and interval of 5 mm to take into consideration tumor motion. A total dose of 50 Gy was delivered at 5 Gy/fraction to 50% isodose line covering 100% of the PTV, with 60 Gy at 6 Gy/fraction to 60% isodose line covering 90% of the CTV, 70 Gy at 7 Gy/fraction to 70% isodose line covering 80% of the GTV, and 10 times finished in 2 weeks, 5 fractions per week. Results The follow-up rate was 97%. The 6 month local tumor response rate was 93%, with CR 86%, and PR 7%. The 1-, 2-year local control rates were both 93%. The 1-, 2-year overall survival rates for the whole group, stage Ⅰ and stage Ⅱ were 97% and 89%, 100% and 92%, 67% and 67%, respectively. The 1-, 2-year progression-free survival were 90% and 86%, respectively. 34% of the patients had acute radiation toxicities (grade 1,2 and 3 in 6,2 and 2 patients, respectively), and 38% late radiation toxicities (grade 1 and 2 in 10 and 1,patients).Conclusions γ-SBRT is a safe and effective treatment regimen,resulted in promising local control and survival with minor toxicity.
LI Hong-qi,WANG Ying-jie,LI Ping et al. Clinical study of stereotactic gamma-ray body radiation therapy for patients with stage Ⅰ/Ⅱ non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2012, 21(4): 321-323.
[1] Xia TY, Li HQ, Sun QX, et al. Promising clinical outcome of stereotactic body radiosurgery in the treatment of patients with medically inoperable stage Ⅰ/Ⅱ non-small cell lung cancer. Int J Radiat Oncol Biol Phys,2005,63:397. [2] 夏廷毅,李宏奇,王颖杰,等.全身γ刀治疗不能手术Ⅰ和Ⅱ期非小细胞肺癌的临床结果.中华放射肿瘤学杂志,2006,15:342-344. [3] 夏廷毅,孙庆选,李平,等.体部γ-刀高分次剂量治疗Ⅰ~Ⅱ期非小细胞肺癌的临床研究.临床肿瘤学杂志,2005,10:20-24. [4] Onishi H, Kuriyama K, Komiyama T, et al. Clinical outcomes ofstereotactic radiotherapy for stage Ⅰ non-small cell lung cancer
using a novel irradiation technique:patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer,2004,45:45-55. [5] Nagata Y, Takayama K, Matsuo Y,et al. Clinical outcomes of a phaseⅠ/Ⅱ study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys,2005,63:1427-1431. [6] McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage on-small cell lung carcinoma:phase Ⅰ study. Int J Radiat Oncol Biol Phys,2005,63:1010-1015. [7] Nishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ non-small cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer,2004,101:1623-1631. [8] 夏廷毅.SBRT临床应用结果的思考.医疗装备,2009,7:1-5. [9] Krol AD, Aussems P, Noordijk EM, et al. Local irradiation alone for peripheral stage Ⅰ lung cancer:could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys,1996,34:297-302. [10] Sulman EP, Chang JY, Liao Z, et al. Exclusion of elective nodal irradiation does not decrease local regional control of non-small cell lung cancer. Int J Radiat Oncol Biol Phys,2005,63:226. [11] The international adjuvant lung cancer trial collaborative group. Cisplatin-based adjuvant chemotherapy in patients with completely resected NSCLC. N Engl J Med,2004,350:351-360. [12] Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected NSCLC. N Engl J Med,2005,352:2589-2597. [13] Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage Ⅰ non-small cell lung cancer. Lung Cancer,2005,48:107-114. [14] Nyman J, Johansson K-A, Hulte′n U. Stereotactic hypofractionated radiotherapy for stage Ⅰ non-small cell lung cancer:matureresults for medically inoperable patients. Lung Cancer,2006,51:97-103. [15] 夏廷毅.头、体γ-刀的临床应用//申文江,王绿化,夏廷毅.放疗学新技术进展.北京:北京科学技术出版社,2003:65-77.
2012, Vol. 21 
